Go Deep
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 24,296 | 8.6 | 1.48 | 0.05 | 106.34 |
| Oct 2026 | 24,273 | 8.7 | 1.49 | 0.05 | 107.31 |
| Oct 2026 | 24,342 | 7.9 | 1.45 | 0.05 | 104.19 |
| Oct 2026 | 24,296 | 8.0 | 1.48 | 0.05 | 106.19 |
| Oct 2026 | 24,067 | 8.7 | 1.61 | 0.05 | 115.68 |
| Oct 2026 | 24,182 | 8.4 | 1.54 | 0.05 | 110.66 |
| Oct 2026 | 24,273 | 8.1 | 1.49 | 0.05 | 106.66 |
Spero Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 258,000.0 | 39,658,000.0 | 3,048,000.0 |
| Net Profit | -9,552,000.0 | -7,203,000.0 | 31,520,000.0 | -7,382,000.0 |
| EPS | -0.2 | -0.1 | 0.6 | -0.1 |
Spero Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 59,619,000.0 | 27,396,000.0 | 96,735,000.0 | 48,579,000.0 | — |
| Net Profit | 8,572,000.0 | -68,566,000.0 | 22,806,000.0 | -46,415,000.0 | — |
| EPS | 0.1 | -1.3 | 0.4 | -1.2 | — |
Spero Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 68,919,000.0 | 110,543,000.0 | 182,390,000.0 | 124,802,000.0 | — |
| Total Liabilities | 9,898,000.0 | 64,420,000.0 | 75,496,000.0 | 48,868,000.0 | — |
| Total Equity | 59,021,000.0 | 46,123,000.0 | 106,894,000.0 | 75,934,000.0 | — |
Owes vs Owns
Spero Therapeutics, Inc. owed $0.16 for every $1 it owned in Jun 2026, down from $0.39 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.16× | 0.14× | 0.58× | 0.41× | 0.39× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Spero Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 58.4%Receivables 36.8%Fixed assets (tangible) 2.1%Other assets 2.6%
How it's funded — Dec 2025
Short-term debt 2.8%Long-term debt 1.4%Payables 1.0%Other liabilities 9.2%Shareholders' equity 85.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 40.3 | 52.9 | 76.3 | 109.1 |
| Receivables | 25.4 | 52.5 | 50.7 | 1.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.5 | 3.1 | 4.2 | 5.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.8 | 2.1 | 51.2 | 9.1 |
| Liabilities & equity | ||||
| Short-term debt | 2.0 | 1.7 | 1.7 | 1.7 |
| Long-term debt | 0.9 | 2.6 | 3.8 | 5.0 |
| Payables | 0.7 | 7.3 | 1.4 | 0.6 |
| Other liabilities | 6.3 | 52.8 | 68.6 | 41.6 |
| Shareholders' equity | 59.0 | 46.1 | 106.9 | 75.9 |
| Net tangible assets | 59.0 | 46.1 | 106.9 | 75.9 |
Spero Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -12,624,000.0 | -23,444,000.0 | -32,995,000.0 | -7,731,000.0 | — |
| Investing Activities | — | — | 0.0 | 33,807,000.0 | 7,672,000.0 |
| Financing Activities | — | 0.0 | 221,000.0 | -29,553,000.0 | 84,050,000.0 |